Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals

Results of Phase 2 research APX3330, a First-in-Class Ref-1 Inhibitor for Diabetic Ocular Diseases Affecting the Retina, Added to Ocuphire Portfolio of Ophthalmic Drug Candidates   Data from Two Recently Completed Nyxol® Phase 2b Studies Accepted for...
Eyes on Sight! Skokie, IL

Eyes on Sight! Skokie, IL

Eyes on Sight! Macular Degeneration Seminar Skokie, IL The Macular Degeneration Association will be returning to beautiful Skokie, IL on Saturday, September 21, 2019. The program series is called“ Eyes on Sight!”. The program will be held at the DoubleTree Chicago...
On